NEW YORK, Oct. 2 – Drug discovery company Pharmacopeia of Princeton, NJ, said Tuesday it has agreed to collaborate with German pharmaceutical company Boehringer Ingelheim to identify lead compounds for an undisclosed target.

Under the terms of the deal, Pharmacopeia will help Boehringer Ingelheim to develop assays and will provide the company with compound samples. In addition, Pharmacopeia will also provide high-throughput screening technology services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.